Richard Gregory
Directeur/Membre du Conseil chez CANBRIDGE PHARMACEUTICALS INC.
Profil
Richard James Gregory is an Independent Non-Executive Director at CANbridge Pharmaceuticals Inc. He previously held positions as an Independent Director at ProMIS Neurosciences, Inc. from 2016 to 2023, Chief Scientific Officer & Director at Canbridge Pharmaceuticals, Inc. (United States), Independent Director at Homology Medicines, Inc., Chief Scientific Officer & Executive VP-Research at ImmunoGen, Inc. from 2015 to 2019, and Head-Research & Development at Genzyme Corp.
from 2011 to 2014.
Dr. Gregory obtained a doctorate degree from the University of Massachusetts in 1986 and an undergraduate degree from Virginia Polytechnic Institute & State University.
Postes actifs de Richard Gregory
| Sociétés | Poste | Début |
|---|---|---|
| CANBRIDGE PHARMACEUTICALS INC. | Directeur/Membre du Conseil | 21/04/2020 |
Anciens postes connus de Richard Gregory
| Sociétés | Poste | Fin |
|---|---|---|
| PROMIS NEUROSCIENCES, INC. | Directeur/Membre du Conseil | 27/04/2023 |
| IMMUNOGEN, INC. | Directeur Technique/Scientifique/R&D | 30/08/2019 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Directeur Technique/Scientifique/R&D | 01/01/2014 |
Canbridge Pharmaceuticals, Inc. (United States)
 Canbridge Pharmaceuticals, Inc. (United States) BiotechnologyHealth Technology Part of CANbridge Pharmaceuticals Inc., Canbridge Pharmaceuticals is a rare disease-focused biopharmaceutical company based in Cambridge, MA. Canbridge Pharmaceuticals, Inc. (United States) was established in 2012 and is committed to researching, developing, and commercializing transformative therapies for rare diseases. | Directeur Technique/Scientifique/R&D | - |
| Q32 BIO INC. | Directeur/Membre du Conseil | - |
Formation de Richard Gregory
| University of Massachusetts | Doctorate Degree |
| Virginia Polytechnic Institute & State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PROMIS NEUROSCIENCES, INC. | Health Technology |
| CANBRIDGE PHARMACEUTICALS INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA. | Health Technology |
Homology Medicines, Inc.
 Homology Medicines, Inc. Pharmaceuticals: MajorHealth Technology Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the translation of proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. The company was founded in March 2015 and is headquartered in Bedford, MA. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Canbridge Pharmaceuticals, Inc. (United States)
Canbridge Pharmaceuticals, Inc. (United States) BiotechnologyHealth Technology Part of CANbridge Pharmaceuticals Inc., Canbridge Pharmaceuticals is a rare disease-focused biopharmaceutical company based in Cambridge, MA. Canbridge Pharmaceuticals, Inc. (United States) was established in 2012 and is committed to researching, developing, and commercializing transformative therapies for rare diseases. | Health Technology |
